Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | GORTEC 2017-01 REACH: avelumab, cetuximab, and radiotherapy in LA-SCCHN

Makoto Tahara • 14 Sep 2024
ESMO 2024
Head and Neck Cancer Antibodies Avelumab Cetuximab Checkpoint Inhibitors
GORTEC 2017-01 REACH

Makoto Tahara, MD, PhD, National Cancer Center Hospital East, Kashiwa, Japan, comment on the Phase III GORTEC 2017-01 REACH trial (NCT02999087), which compared avelumab, cetuximab with radiotherapy against standard-of-care (SOC) treatments in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). In cisplatin-unfit patients, the combination improved progression-free survival (PFS) and reduced distant metastasis rates but did not enhance overall survival (OS). This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Makoto Tahara

Setanaxib and pembrolizumab in head and neck squamous cell carcinoma
0:58
Setanaxib and pembrolizumab in head and neck squamous cell carcinoma
Makoto Tahara • 14 Sep 2024
JCOG1008: final analysis of weekly versus 3-weekly cisplatin and radiotherapy in SCCHN
0:43
JCOG1008: final analysis of weekly versus 3-weekly cisplatin and radiotherapy in SCCHN
Makoto Tahara • 14 Sep 2024

Related Videos

NRG-HN015: Phase II trial of perioperative systemic therapy in recurrent head and neck cancer
3:11
NRG-HN015: Phase II trial of perioperative systemic therapy in recurrent head and neck cancer
Nabil Saba • 1 Jun 2026
INO-3107 and B-cell immunity: implications for HPV-associated cancers
1:29
INO-3107 and B-cell immunity: implications for HPV-associated cancers
Nabil Saba • 1 Jun 2026
B-cell responses in recurrent respiratory papillomatosis treated with DNA immunotherapy INO-3107
3:02
B-cell responses in recurrent respiratory papillomatosis treated with DNA immunotherapy INO-3107
Nabil Saba • 1 Jun 2026
Phase III MACE trial: metronomic chemotherapy after surgery in oral cavity squamous cell carcinoma
2:40
Phase III MACE trial: metronomic chemotherapy after surgery in oral cavity squamous cell carcinoma
Nandini Menon • 31 May 2026
The content of VJOncology is intended for healthcare professionals